Download Free Sample
Buy Now
Epigenetic Therapies for Cancer Market Overview
The global epigenetic therapies for cancer market size, valued at USD 14.32 billion in 2024, is projected to reach USD 16.93 billion in 2025 and USD 66.12 billion by 2035, representing a CAGR of 14.6% during the forecast period.
.webp "Epigenetic Therapies for Cancer Market Distribution by Geographical Regions, Till 2035 (USD Billion)") |
Epigenetic Therapies for Cancer Market: In Summary
- Epigenetic therapies have shown promising results, particularly in hematological cancers like lymphoma and leukemia, by reversing abnormal gene expression patterns without altering the DNA sequence.
- Advances in molecular diagnostics / profiling techniques (next-generation sequencing, and liquid biopsies) enable precise identification of epigenetic changes in cancer cells, allowing for the development of targeted epigenetic drugs and biomarker-driven patient selection strategies.
- The convergence of epigenomics, genomics, and proteomics data accelerates epigenetic drug discovery by providing a comprehensive understanding of disease mechanisms and enabling the development of highly precise drugs.
- In terms of type of therapy, DNA Methyltransferase Inhibitors (DNMTi) currently hold the largest market share due to their proven efficacy in silencing cancer-promoting genes. However, Bromodomain and Extra-Terminal Domain (BET) Inhibitors are anticipated to exhibit a higher CAGR, as they effectively target proteins that regulate gene expression to inhibit cancer cell growth.
- Hematological cancers dominate the market, accounting for 60% of the share, largely due to the approval of DNMTi and HDACi drugs for these malignancies. Nevertheless, the solid tumors segment is expected to register a higher CAGR, driven by increasing research and development efforts to target these prevalent cancers.
- North America currently holds the largest share (45%) of the epigenetic therapies for cancer market. This dominance is due to robust research activities, ongoing clinical trials for targeted therapies, and strong support from regulatory agencies for next-generation epigenetic cancer drugs. The Asia-Pacific region is projected to experience the fastest growth, primarily fueled by increasing government initiatives and funding to support research and development of advanced epigenetic cancer drugs in the region.
- A significant trend is the shift towards combination therapies, integrating epigenetic drugs with immunotherapies to enhance efficacy, overcome drug resistance, and make cancer cells more visible to the immune system. This approach has proven more effective than monotherapy in oncology.
- Industrial players, such as Pfizer (US), Merck (US), and GSK (UK) are increasing research initiatives to develop more innovative drugs, which is expected to drive the market in the future.
Epigenetic Therapies for Cancer Market Introduction
Cancer has been a major cause of concern for the healthcare industry, creating immense pressure to develop advanced therapies. As per the latest report of National Institute of Health, in 2025, nearly 2,041,910 cancer cases are projected to occur in the US. To date, several cancer therapeutics has been developed to treat patients and reduce the risk of mortality. Pharmaceutical industry is exploring more innovative therapies, such as epigenetics therapies, to target wide range of cancer.
Notably, epigenetic therapies has shown promising results during various clinical trials, specifically lymphoma and leukemia (form of liquid tumors). These therapies helps to reverse abnormal gene expression patterns within cancerous cells by targeting epigenetic mechanisms. It is important to highlight here that epigenetic therapies helps to restore gene activity mechanism (on / off gene switch) without altering the DNA sequence, specifically silencing cancer-promoting genes.
Unlock Deeper Insights – Schedule Your Personalized Workshop Today!
Several research programs are underway to develop advanced epigenetic therapies for targeting cancer or solid tumors. For instance, in January 2025, a study published in John Hopkins Medicine highlighted that a team of researchers at Johns Hopkins Kimmel Cancer Center and Chinese Academy of Sciences identify new epigenetic approach to target colorectal cancer. During this study, researchers found a mouse protein that disrupts cancer-causing chemicals within genes associated with colorectal cancer cells. This new finding has further triggered research on epigenetics therapies, which is expected to offer lucrative opportunities for innovation and investment in epigenetic therapies for cancer market.
Epigenetic Therapies for Cancer Market: Report Attributes
| Key Report Attribute | Details | |
| Historical Trend | Since 2020 | |
| Forecast Period | Till 2035 | |
| Market Size 2025 | USD 16.93 Billion | |
| Market Size 2035 | USD 66.12 Billion | |
| CAGR (Till 2035) | 14.6% | |
The global epigenetic therapies for cancer market analysis also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as type of therapy, application area, route of administration, end user, geographical regions, and leading players.
In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of industry’s evolution.
Recent Developments in Epigenetic Therapies for Cancer Market
Several recent developments in the field of epigenetic therapies for cancer industry have occurred, and we outlined some of these below.
- In April 2025, Pfizer presented updated results from its ongoing Phase I studies that indicates the dosing strategy for two molecules targeting epigenetic regulators: mevrometostat (an investigation EZH2 inhibitor), which is currently being evaluated in combination with XTANDI for metastatic castration-resistant prostate cancer, and PF-07248144 (first-in-class KAT6 inhibitor for ER+ / HER2) for metastatic breast cancer.
- In April 2025, a study co-led by the University of Maryland School of Medicine researchers published in Cancer Research identified a 'master regulator' gene, ZNFX1, which act as a biomarker to assist in treatment of patients with therapy resistance ovarian cancer.
- In February 2025, a team of scientists (Song, J., Yang, P., Chen, C. et al.) highlighted that targeting epigenetic regulators emerge as a promising solution to overcome cancer therapy resistance.
See What’s in the Full Report – Request Your Complimentary Insights!
Epigenetic Therapies for Cancer Market Segmentation Insights
The market report provides comprehensive information on epigenetic therapies for cancer market players who are currently active across various segments of the industry as mentioned in the table below.
Epigenetic Therapies for Cancer Market: Market Segmentation
| Market Segmentation | Details | |
| Type of Therapy |
|
|
| Application Area |
|
|
| Route of Administration |
|
|
| End User |
|
|
| Geographical Regions |
|
|
| Market In North America |
|
|
| Market In Europe |
|
|
| Market in Asia-Pacific |
|
|
| Market in Middle East & Africa |
|
|
| Market in Latin America |
|
|
Industry Experts on Epigenetic Therapies for Cancer Market
The global personalized cancer epigenetic treatments market is gaining traction due to the growing demand for target specific solutions for cancer treatment. Selective BET blockade is redefining the pathway to fix reversible epigenetic in solid tumors.
'There is a tremendous unmet need to develop new approaches to therapeutically block DNA methylation abnormalities to treat patients with solid tumors,' said Stephen Baylin, (M.D., the Virginia and D.K. Ludwig Professor of Oncology and Medicine at Johns Hopkins and co-director of the Johns Hopkins Kimmel Cancer Center Genetics and Epigenetics Program).
Epigenetic Therapies for Cancer Market Share Insights
Market Share by Type of Therapy: Does DNA methyltransferase Inhibitors Market Expand in the Future?
- Based on the type of therapy, the global market is distributed across DNA methyltransferase inhibitors (DNMTi), histone deacetylase inhibitors (HDACi), histone methyltransferase inhibitors, bromodomain and extra-terminal domain (BET) inhibitors, and others. According to epigenetic therapies for cancer market report, the DNA methyltransferase inhibitors segment holds the highest share of the market. This can be attributed to the fact that the DNA methyltransferase inhibitors have shown promising outcomes in the treatment of cancer by silencing the genes in cancer cells.
- It is important to highlight that the bromodomain and extra-terminal domain (BET) inhibitors segment is likely to grow at a higher CAGR in the future. This can be ascribed to the fact that BET inhibitors can target the proteins that interact with acetylated histones, that further helps to regulate the gene expression to inhibit the growth of cancer cell.
Have Questions? Let's Get Them Answered
Market Share by Application Area: How HDAC Inhibitors are Transforming Treatment Resistance Patterns in Hematological Malignancies?
-
The global market is segmented across different application area, such as solid tumors, hematological cancers, and others. Among these, the hematological cancers segment is holding 60% of the cancer epigenetics market share. This can be attributed to the rising approval of the DNA methyltransferase inhibitors (DNMTi), and histone deacetylase inhibitors (HDACi) drugs by the USFDA to treat hematological malignancies.
-
It is worth noting that the solid tumors segment is anticipated to register higher CAGR during the forecast period. The rising research on epigenetic therapies to target solid tumors is the key driver for unprecedented growth of this segment.
Market Share by Route of Administration: Why Do Injectable Segment Holds the Highest Share?
- Based on the route of administration, the global market is segmented into oral, subcutaneous and injectables. According to the epigenetic therapies for cancer market forecast, the injectables segment is dominating the market by holding maximum share. This can be attributed to the fact that injections helps to surpass the gastrointestinal barriers and deliver drug at targeted location for higher efficiency.
- Notably, the injectables segment will continue to grow at a higher CAGR in the future. This reflects the higher adoption of injectable mode for delivering epigenetic therapies.
Market Share by End User: Cancer Research Institutes Will Continue to Maintain Its Dominance in the Future
- The end user segment highlights the distribution of global market across hospitals, cancer research institutes, specialty clinics, and others. According to the epigenetic therapy for cancer industry analysis, the cancer research institutes segment is dominating the market by securing highest share. This dominance is due to the increasing research on epigenetic therapies to target cancerous cells.
- It is important to highlight here that this segment will continue to maintain its dominance and is likely to grow at a higher CAGR during the forecast period. The ongoing research and clinical trials on the epigenetic therapies are likely to be the robust reason for unprecedented growth of this segment.
Market Share by Geographical Regions: How Clinical Trial Outcomes Driving USFDA Approvals For Next-Generation Epigenetic Cancer Drugs in North America?
- The global market is distributed across North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Based on our analysis, currently the North America is accounting for 45% of the epigenetic therapies for cancer market growth. This dominance reflects from the increasing research on epigenetic therapies, ongoing clinical trials on the targeted therapies, and support from the regulatory agencies for next-generation epigenetic cancer drugs.
- The market for epigenetic therapy for cancer in Asia-Pacific is expected to grow at a higher CAGR during the forecast period. This immense growth is due to the rising government initiatives to support research on advanced epigenetic cancer drugs.
Epigenetic Therapy for Cancer Market: Report Deliverables
| Report Deliverables | Details | |
| Excel Data Packs (Complimentary) | Available | |
| Key Epigenetic Therapy for Cancer Companies Profiled |
(A complete list of companies captured is available in the report) |
|
| PowerPoint Presentation (Complimentary) | Available | |
| Customization Scope | 15% Free Customization | |
Epigenetic Therapy for Cancer Market Key Takeaways
The “Epigenetic Therapy for Cancer Market Report: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics, and future opportunities for epigenetic therapy for cancer industry players. The market research report lays emphasis on the epigenetic therapies that are being developed for the cancer treatment. Key takeaways of the market report are briefly discussed below.
Competitive Landscape: How is the Competitive Landscape Shaping Up Between Big Pharma and Biotech Firms?
The emerging regulatory pathways for epigenetic biomarker-guided cancer treatment selection has catered the attention of industrial players for innovation in this field. Overall, the market for epigenetic therapy for cancer is moderately competitive, featuring the presence of well-established pharmaceutical players and research institutes. Notably, the cancer research institutes, and pharmaceutical industrial players are co-jointly focusing on the development of next-generation epigenetic therapy to treat cancer. As more market players enter into the industry, this market will remain competitive for the long term.
Market Size Analysis: What Makes Combination Epigenetic-Immunotherapy Approaches More Effective Than Monotherapy in Oncology?
In 2025, the epigenetic therapy for cancer market is expected to be valued at USD 16.93 billion. This unprecedented growth is driven by the rising demand for combination epigenetic immunotherapy to treat cancer with higher efficacy. Notably, the combination approach is widely used to mitigate the concern of off-target effects.
Market Drivers: What Factors are Driving the Cancer Epigenetic Therapy Industry?
Epigenetic therapies have shown promising outcomes to treat cancer specifically malignant tumors, which is expected to drive its demand in the future. Several other promising factors that are driving the market growth are listed below:
Rising Demand for Precision Medicine in Oncology: Are Biomarker-Driven Patient Selection Strategies Increasing Adoption Rates?
The rising trend of oncology precision medicine is the key driver for the market. Notably, the availability of advanced molecular profiling techniques, such as next generation sequencing and liquid biopsies helps to identify the genetic mutations, and epigenetic changes that drivers the growth of cancerous cells. These detailed profiling helps to identify targeted epigenetic drugs that precisely target these abnormalities. Additionally, this approach also helps to identify the precision oncology epigenetic biomarkers that allow clinicians to select patients that are benefitted from epigenetic drugs.
Rising Next-Generation Epigenetic Drugs Pipeline: What's the Addressable Market for Next-Generation Epigenetic Drug Classes?
The emergence of novel epigenetic drug targets beyond histone deacetylase inhibitors cancer to target broad range of epigenetic regulators in individual tumors are offering new possibilities for industrial players. Notably, this precision approach helps to develop patient specific next-generation epigenetic drugs to treat cancer. Currently, several epigenetic drugs are being evaluated under clinical trials and researchers are exploring next-generation epigenetic drugs to target tumors which is likely to drive the market in the future.
Market Challenges: What are the Key Challenges in the Market?
High Development Cost of Epigenetic Therapy
Notably, the high cost associated with the development of epigenetic therapy is likely to slow the uptake of drugs in the community. It is worth mentioning that the development of drug require multiple clinical trials, drug study and approval from the regulatory authorities. The entire process may increase the expenses of epigenetic drug development, creating challenges for the market players.
Off-Target Toxicities: How Off-Target Toxicities Create Barriers To Scaling Personalized Epigenetic Therapies In Solid Tumor Treatment?
It is worth noting that when an epigenetic drug inhibits an enzyme that regulates the gene processes (histone deacetylase or DNA methyltransferase), it can affect both cancerous and healthy cells. This off-target toxicity due to lack of target-specificity may lead to undesirable side effects and impact normal cell function. Therefore, the off-target toxicity may create challenges to achieve high therapeutic efficiency.
Future Trends: What are the Top Epigenetic Cancer Drugs Market Trends Shaping the Industrial Growth?
Driven by the ongoing research, several market players are focusing on the emerging trends that are shaping the market growth. Some of the potential opportunities in this industry are listed below:
Increasing Shift Towards Combination Therapies: How do Combination Therapies with Immunotherapy Impact Market Dynamics?
In order to enhance the therapeutic efficacy, several market players are focusing on the development of combination therapies that includes the combination of epigenetics and immunotherapy drugs. This significant combination helps to overcome the cancer drug resistance challenges, specifically when immune checkpoint inhibitors does not respond into patient body. Additionally, the combination of epigenetic inhibitor can induce the expression of neoantigens which makes cancer cells more visible to immune system, thereby killing it. As researchers continue to explore combination therapies, this market is expected to grow dynamically in the future.
Integration of Multi-Omics Studies: Why Multi-Omics Integration Accelerates Epigenetic Drug Discovery Timelines?
The notable shift towards multi-omics integration has significantly accelerates the discovery of epigenetic drugs discovery. Notably, the integration of multi-omics (epigenomics, genomics and proteomics data) allow researcher to identify epigenetic dysregulation in cancer. This comprehensive view helps to understand disease mechanism and develop precise drugs to treat cancer.
Don't Pay for What You Don't Need. Individual Sections of the Report Are Available for Purchase Now.
What are the Top Strategic Moves of the Epigenetic Therapy for Cancer Market Players?
With growing pipeline of epigenetic combination therapy trials under clinical studies, numerous players are actively undertaking strategic initiatives to strengthen the market growth. Some of the notable strategies adopted by the market players are listed below:
| Company | Leading Epigenetic Assets | Key Strategic Moves |
| Ipsen / Epizyme (France) | Tazemetostat (EZH2i) | Sarcoma label expansion, pembrolizumab combo |
| GSK (UK) | JNJ-64619178 (PRMT5), belinostat HDACi | Multi-omics companion Dx integration to enhance study on epigenomics |
| Bristol Myers Squibb (US) | CC-90010 (BETi), 5-azacitidine franchise | Fixed-dose azacitidine/cedazuridine oral HMA approved |
Epigenetic Therapy for Cancer Market Report Coverage
- An Infographic Executive Summary
- Regulatory Scenario
- Comprehensive Database of Leading Players
- Competitive Landscape
- Porter’s Five Forces Analysis
- Company Competitiveness Analysis
- Startup Ecosystem in the Epigenetic Therapy for Cancer Market
- Company Profiles
- Patent Analysis
- Partnerships and Collaborations
- Grant Analysis
- Funding and Investment Analysis
- Clinical Trial Analysis
- Market Opportunity Analysis
- SWOT Analysis
Glossary
- DNMTi (DNA Methyl-Transferase Inhibitors): These are enzymes responsible for adding methyl groups (CH3) to DNA, primarily at cytosine residues within CpG dinucleotides (a cytosine followed by a guanine in the DNA sequence). This process is called DNA methylation.
- HDACi (Histone Deacetylase Inhibitor): These are enzymes that remove acetyl groups from lysine residues on proteins, most famously on the N-terminal tails of histone proteins. HDACs are often contrasted with histone acetyltransferases (HATs), which add acetyl groups.
- Epigenomic: The epigenome refers to the multitude of chemical compounds and proteins that can attach to DNA and histones (proteins around which DNA is wrapped) and direct actions such as turning genes on or off, controlling the production of proteins in specific cells, and influencing chromatin structure.
From the Author’s Desk
Author’s View on Epigenetic Therapy for Cancer Market
Epigenetic therapy for cancer is a whole new approach to target cancerous cells with a target-specific approach without altering the DNA sequence. This new research has offered dynamic possibilities for the pharmaceutical industry to develop next-generation epigenetic drugs with higher efficacy to treat solid tumors. The next decade will witness epigenetic therapies evolving from niche applications to cornerstone treatments, driven by improved formulations, advanced molecular diagnostics, and groundbreaking technologies. Notably, the technologies like BET-PROTACs and CRISPR epigenome modifiers that are fundamentally reshaping our approach to cancer treatment by precisely manipulating the very software of our cells.
Customization Opportunities
At Roots Analysis, we genuinely care about your success and understand that your business requirements are unique. While our market research reports provide valuable insights, we recognize that they might not cover every aspect you need to make well-informed strategic decisions. To account for that, we offer 15% free report customization tailored to your specific needs. Whether you require additional quantitative analysis, qualitative insights, or any other information related to the electric vehicles market, reach out to us today at support@rootsanalysis.com
